The Drugs Don't Work

This article examines one particular set of technologies arising from developments in human genetics, those aimed at improving the targeting, design and use of conventional small molecule drugs - pharmacogenetics. Much of the debate about the applications and consequences of pharmacogenetics has been highly speculative, since little or no working technology is yet on the market. This article provides a novel analysis of the development of pharmacogenetics, and the social and ethical issues it raises, based on the sociology of technological expectations. In particular, it outlines how two alternative visions for the development of the technology are being articulated and embedded in a range of heterogeneous discourses, artefacts, actor strategies and practices, including: competing scientific research agendas, experimental technologies, emerging industrial structures and new ethical discourses. Expectations of how pharmacogenetics might emerge in each of these arenas are actively shaping the trajectory of this nascent technology and its potential socio-economic consequences.

[1]  Amalia M. Issa,et al.  Ethical perspectives on pharmacogenomic profiling in the drug development process , 2002, Nature Reviews Drug Discovery.

[2]  M. Mosteller,et al.  APPLICATIONS OF PHARMACOGENETICS TO DRUG DEVELOPMENT: THE GLAXO WELLCOME EXPERIENCE* , 2000, Drug metabolism reviews.

[3]  M. Boyce-Jacino,et al.  A SNPshot: pharmacogenetics and the future of drug therapy. , 2000, Trends in biotechnology.

[4]  A. Marshall.  Getting the right drug into the right patient , 1998, Nature Biotechnology.

[5]  M R Anderlik,et al.  Privacy and confidentiality of genetic information: what rules for the new science? , 2001, Annual review of genomics and human genetics.

[6]  J W Jukema,et al.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.

[7]  Amalia M. Issa,et al.  Ethical considerations in clinical pharmacogenomics research. , 2000, Trends in pharmacological sciences.

[8]  T. Pinch,et al.  The Social Construction of Facts and Artefacts: or How the Sociology of Science and the Sociology of Technology might Benefit Each Other , 1984 .

[9]  U. A. Meyers.  Molecular genetics and the future of pharmacogenetics , 1990 .

[10]  R. Chadwick.  Criteria for genetic screening: the impact of pharmaceutical research , 1999 .

[11]  J. Barker,et al.  Pharmacogenetics in clinical dermatology , 2002, The British journal of dermatology.

[12]  A. Motulsky.  Bioethical problems in pharmacogenetics and ecogenetics. , 1978, Human genetics. Supplement.

[13]  W. Evans,et al.  Pharmacogenetics as a Molecular Basis for Individualized Drug Therapy: The Thiopurine S-methyltransferase Paradigm , 1999, Pharmaceutical Research.

[14]  A. Roses.  Pharmacogenetics and the practice of medicine , 2000, Nature.

[15]  D. Cheek,et al.  Pharmacogenomics : Continuing care in adult cardiology: Living with a cardiac diagnosis , 2000 .

[16]  O. Corrigan,et al.  A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises. , 2002, Social science & medicine.

[17]  M. Ingelman-Sundberg.  Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy , 2001, Journal of internal medicine.

[18]  A. Persidis.  Pharmacogenomics and diagnostics , 1998, Nature Biotechnology.

[19]  G. Sutherland,et al.  The “new genetics” and clinical practice , 2003, The Medical journal of Australia.

[20]  Stuart S. Blume,et al.  Insight and Industry: On the dynamics of technological change in Medicine Cambridge , 1991 .

[21]  J. Kurth,et al.  The impact of pharmacogenetics on the future of healthcare. , 1997, Current opinion in biotechnology.

[22]  N. Brown,et al.  Contested Futures: A Sociology of Prospective Techno-Science , 2000 .

[23]  Pharmacogenetics: the ethical context , 2001, The Pharmacogenomics Journal.

[24]  E. Vesell,et al.  Genetic Variation as a Guide to Drug Development , 1998, Science.

[25]  Jean-Claude Kaplan,et al.  Genomics and medicine: an anticipation. From Boolean Mendelian genetics to multifactorial molecular medicine. , 2000, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[26]  K. Lackner,et al.  Pharmacogenomics: implications for laboratory medicine. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[27]  John D. W. Guice,et al.  Designing the future: the culture of new trends in science and technology , 1999 .

[28]  A. Issa,et al.  Apolipoprotein E Genotyping for Pharmacogenetic Purposes in Alzheimer's Disease: Emerging Ethical Issues , 2000, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[29]  J. Kurth.  Pharmacogenomics: Future Promise of a Tool for Identifying Patients at Risk , 2000 .

[30]  C. Caldas,et al.  Impact of genomics on drug discovery and clinical medicine. , 2000, QJM : monthly journal of the Association of Physicians.

[31]  C. Coleman,et al.  Closing the gaps in genetics legislation and policy: a report by the new york state task force on life and the law. , 2001, Genetic testing.

[32]  W. Kalow.  Pharmacogenetics: Past and future , 1990 .

[33]  S. Wyatt,et al.  Talking about the future: Metaphors of the Internet , 2000 .

[34]  S. Akhtar.  Pharmacogenomics: Are pharmacists ready for genotyped prescribing? , 2002 .

[35]  Alun McCarthy.  Pharmacogenetics: Implications for drug development, patients and society , 2000 .

[36]  Paul Martin.  Great expectations: the construction of markets, products and user needs during the early development of gene therapy in the USA , 2001 .

[37]  A Regalado,et al.  Inventing the pharmacogenomics business. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[38]  P. Oestreicher.  4th Annual Pharmacogenomics and Medicine Lectures. , 2001, Pharmacogenomics.

[39]  Armin Grunwald,et al.  Vision Assessment: Shaping Technology in 21st Century Society , 2000 .

[40]  Paul A. Martin.  Genetic governance: The risks, oversight and regulation of genetic databases in the UK , 2001 .

[41]  C. Elliott.  Pharma buys a conscience. , 2001, The American prospect.

[42]  M. Callon.  Society in the making: The study of technology as a tool for sociological analysis , 1987 .

[43]  R M. Norton,et al.  Clinical pharmacogenomics: applications in pharmaceutical R&D. , 2001, Drug discovery today.

[44]  D W Nebert,et al.  Pharmacogenomics: out of the lab and into the community. , 2001, Trends in biotechnology.

[45]  Mark A. Rothstein,et al.  Ethical and legal implications of pharmacogenomics , 2001, Nature Reviews Genetics.

[46]  D. Nebert.  Pharmacogenetics: 65 candles on the cake , 1997 .

[47]  R. Kisabeth,et al.  Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care. , 2001, Mayo Clinic proceedings.

[48]  C. Moyses.  Pharmacogenetics, genomics, proteomics : the new frontiers in drug development , 1999 .

[49]  G Hughes,et al.  Managing acute anaphylaxis , 1999 .

[50]  Leach Dh.  A new world view of genetics service models. , 2000, Online journal of issues in nursing.

[51]  K. Lindpaintner.  Genetics in drug discovery and development: challenge and promise of individualizing treatment in common complex diseases. , 1999, British medical bulletin.

[52]  M. W. Foster,et al.  Pharmacogenetics, race, and ethnicity: social identities and individualized medical care. , 2001, Therapeutic drug monitoring.

[53]  A. Hedgecoe.  Reinventing diabetes: Classification, division and the geneticization of disease , 2002 .

[54]  W. Weber,et al.  The legacy of pharmacogenetics and potential applications. , 2001, Mutation research.

[55]  Arie Rip,et al.  The Narrative Shaping of a Product Creaction Process , 2017 .

[56]  W. Kalow,et al.  Pharmacogenetics in perspective. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[57]  J. Kaplan.  Génomique et médecine: réflexions prospectives. De la génétique booléeene des lois de Mendel à une médecine moléculaire multifactorielle. , 2000 .

[58]  W. Haseltine.  Not quite pharmacogenomics , 1998, Nature Biotechnology.

[59]  C. Rotimi,et al.  The new genetics in clinical practice , 1998, BMJ.

[60]  D. Collier,et al.  Pharmacogenetic prediction of clozapine response , 2000, The Lancet.

[61]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[62]  G. Tsongalis,et al.  Pharmacogenomics: will it change the field of medicine? , 2001, Clinica chimica acta; international journal of clinical chemistry.

[63]  R C Elston,et al.  Testing drug response in the presence of genetic information: sampling issues for clinical trials. , 2000, Pharmacogenetics.

[64]  U. Meyer.  Pharmacogenetics and adverse drug reactions , 2000, The Lancet.

[65]  G. Ginsburg,et al.  Personalized medicine: revolutionizing drug discovery and patient care. , 2001, Trends in biotechnology.

[66]  P. Joubert,et al.  Opportunities and strategies for introducing pharmacogenetics into early drug development. , 2001, Drug discovery today.

[67]  C. Giaquinto,et al.  Variable use of therapeutic interventions for children with human immunodeficiency virus type 1 infection in Europe , 2000, European Journal of Pediatrics.

[68]  S. Liggett.  Pharmacogenetic applications of the Human Genome project , 2001, Nature Medicine.

[69]  E. Jazwinska.  Exploiting human genetic variation in drug discovery and development. , 2001, Drug discovery today.

[70]  R. Weinshilboum.  The genomic revolution and medicine. , 2002, Mayo Clinic proceedings.

[71]  G. Webb.  Evolution not revolution. , 2003, Journal of radiological protection : official journal of the Society for Radiological Protection.

[72]  A. Persidis.  Pharmacogenomics and diagnostics , 1998, Nature Biotechnology.

[73]  W. Evans,et al.  Pharmacogenomics: unlocking the human genome for better drug therapy. , 2001, Annual review of pharmacology and toxicology.

[74]  P. Rioux.  Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[75]  Allen D. Roses,et al.  Genome-based pharmacogenetics and the pharmaceutical industry , 2002, Nature Reviews Drug Discovery.

[76]  A. Persidis.  The business of pharmacogenomics , 1998, Nature Biotechnology.

[77]  E. Oren,et al.  Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.

[78]  Paul Martin,et al.  Genes as drugs: the social shaping of gene therapy and the reconstruction of genetic disease , 1999 .

[79]  J. Potter,et al.  Pharmacogenetic screening and therapeutic drugs. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[80]  B. Salter,et al.  Human genetic technologies, European governance and the politics of bioethics , 2002, Nature Reviews Genetics.

[81]  Family consent and the pursuit of better medicines through genetic research , 2001, The Journal of continuing education in the health professions.

[82]  J. Bell.  Genetics of common disease: implications for therapy, screening and redefinition of disease. , 1997, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[83]  M. A. Elston,et al.  The sociology of medical science and technology , 1999 .

[84]  S. Gauthier,et al.  Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[85]  M. H. Ensom,et al.  Pharmacogenetics , 2001, Clinical pharmacokinetics.

[86]  Guiding Icarus: Merging Bioethics With Corporate Interests , 2003 .

[87]  C R Cantor.  Pharmacogenetics becomes pharmacogenomics: wake up and get ready. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[88]  D. Weatherall.  The new genetics and clinical practice , 1982 .

[89]  S. Webb,et al.  Insight and industry: on the dynamics of technological change in medicine , 1992, Medical History.

[90]  P. Manasco,et al.  Pharmacogenetics: theRx perspective , 2001 .

[91]  Nicholas Schork,et al.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment , 1999, Nature Genetics.

[92]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  A. Davis,et al.  Pharmacogenetics research network and knowledge base: 1st annual scientific meeting. , 2001, Pharmacogenomics.

[94]  Harry Greenberg,et al.  Principles, organization, and operation of a DNA bank for clinical trials: a Department of Veterans Affairs cooperative study. , 2002, Controlled clinical trials.

[95]  Wiebe E. Bijker,et al.  The social construction of technological systems , 1996 .

[96]  C. Wolf,et al.  Science, medicine, and the future: Pharmacogenetics. , 2000, BMJ.

[97]  D. Callahan.  Doing good and doing well. , 2001, The Hastings Center report.

[98]  John A. Robertson,et al.  Consent and privacy in pharmacogenetic testing , 2001, Nature Genetics.

[99]  A. Read.  Genetics of Common Diseases , 1998, BMJ.

[100]  A. Roses,et al.  Pharmacogenetics and future drug development and delivery , 2000, The Lancet.

[101]  A. Hedgecoe,et al.  Terminology and the Construction of Scientific Disciplines: The Case of Pharmacogenomics , 2003 .

[102]  A. Shelling,et al.  Role of p53 in drug resistance in ovarian cancer , 1997, The Lancet.

[103]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.